IgAN的发病机制及临床治疗研究进展(5)
[21] Cheng J，Zhang X，Tian J，et al.Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy：a meta-analysis[J].Int J Clin Pract，2012，66(10)：917-923.
[22] Li P，Chen Y Z，Lin H L，et al.Abelmoschus manihot-a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy：study protocol for a randomized controlled trial[J].Trials，2017，18(1)：170.
[23]郝海斌.中醫与中西医结合治疗IgA肾病的效果对比分析[J].临床医学研究与实践，2017，2(11)：107-108.
[24] Roberts I S，Cook H T，Troyanov S，et al.The Oxford classification of IgA nephropathy： pathology definitions， correlations，and reproducibility[J].Kidney Int，2009，76(5)：546-556.
[25] Shao X，Li B，Cao L，et al.Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy：a systematic review and meta-analysis[J].Oncotarget，2017，8(28)：46436-46448.
[26] Min P，Ji Z，Li Z，et al.Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy： a retrospective study[J].BMC Nephrol，2017，18(1)：231.
(收稿日期：2017-11-03), 百拇医药(李壮林 高丽)
[22] Li P，Chen Y Z，Lin H L，et al.Abelmoschus manihot-a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy：study protocol for a randomized controlled trial[J].Trials，2017，18(1)：170.
[23]郝海斌.中醫与中西医结合治疗IgA肾病的效果对比分析[J].临床医学研究与实践，2017，2(11)：107-108.
[24] Roberts I S，Cook H T，Troyanov S，et al.The Oxford classification of IgA nephropathy： pathology definitions， correlations，and reproducibility[J].Kidney Int，2009，76(5)：546-556.
[25] Shao X，Li B，Cao L，et al.Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy：a systematic review and meta-analysis[J].Oncotarget，2017，8(28)：46436-46448.
[26] Min P，Ji Z，Li Z，et al.Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy： a retrospective study[J].BMC Nephrol，2017，18(1)：231.
(收稿日期：2017-11-03), 百拇医药(李壮林 高丽)